News

 

NEWS

ViewPoint Therapeutics Raises $4 Million in Series A Financing

ViewPoint Therapeutics Raises $4 Million in Series A Financing ViewPoint Therapeutics, Inc., a privately-held biotechnology company pioneering the development of crystallin stabilizers to prevent and treat cataracts and presbyopia, today announced the closing of a $4 million Series A financing. The transaction was co-led by Mission Bay Capital and Lagunita BioSciences LLC. Also included in the syndicate was healthcare-dedicated investor, […]

Read more

Miroculus Acquires Microfluidics Firm Kapplex

MicroRNA Diagnostics Developer Miroculus Acquires Microfluidics Firm Kapplex Miroculus, a San Francisco startup developing microRNA-based diagnostic tests, said Monday that it has acquired Toronto-based microfluidics firm Kapplex for an undisclosed amount. Miroculus emerged from stealth mode earlier this year at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference. It aims to tap into the growing evidence that miRNAs can serve as useful […]

Read more

Dow AgroSciences and TeselaGen to collaborate

A new collaboration between Dow AgroSciences and TeselaGen Biotechnology Inc. is designed to produce a biological design automation platform that can speed up discovery work for new agricultural products. “TeselaGen has created a powerful suite of tools for DNA design,” said Daniel R. Kittle, Ph.D., vice president, research and development, Dow AgroSciences. “These tools have the potential to accelerate our […]

Read more

Perlstein Lab continues their rare disease drug discovery

Perlstein Lab, or PLab as it is also known, continues to hone its automated drug discovery platform and presents its latest iteration Wednesday March 23rd at Y Combinator Demo Day. The platform they created helps the bio startup focus on finding cures for rare diseases rather than common ones. This novel approach is different from most Big Pharma labs and […]

Read more

Startup Miroculus Shares Vision for Rapid, Inexpensive miRNA Diagnostics at Tri-Con

Molecular diagnostics startup Miroculus is going all in on microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases and even tracking an individual’s general physiological well-being at the point of care and in resource-poor areas of the world, the company’s chief technology officer said this week. In a keynote presentation at Cambridge Healthtech Institute’s Molecular […]

Read more

IBM Watson adds Tiatros patient-centered social network to system

San Francisco start-up Tiatros, a doctor-driven, patient-centered social network, has joined the IBM Watson Ecosystem, the companies announced March 2 at HIMSS16. Tiatros was designed to allow physicians, with the consent of patients, to create a social network around the patient, including all doctors involved in their treatment and their family members. The first user of the platform was the […]

Read more

Immucor and Sirona Genomics receive the CE mark for Mia Fora NGS system for HLA typing

Immucor and Sirona Genomics announced this week that they have received the CE mark for their Mia Fora NGS system for HLA typing. The system is a high-resolution HLA typing solution for accurate coverage and analysis of 11 HLA genes. It is adapted for use on the Illumina MiSeq. The companies expect to launch a higher volume testing kit for […]

Read more

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth QB3@953, a biotech incubator, has been so successful that many of the startups housed there are searching for larger laboratories in Southside San Francisco. But their moves have been stymied by high rents and real estate prices, as well as a lack of space for midsize companies. The incubator, launched almost […]

Read more

Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors

Pfizer ($PFE) announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease […]

Read more

Amarantus Inks Deal to Merge Dx Unit with Avant Diagnostics

NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings announced today that it has signed a letter of intent to merge its Amarantus Diagnostics subsidiary with Avant Diagnostics. Upon the close of the merger, Avant will issue Amarantus Bio 80 million shares of its common stock, representing roughly 45 percent of the combined company’s outstanding shares. Avant will also issue Amarantus Bio […]

Read more
Page 5 of 10« First...34567...10...Last »

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    09:00-11:00
    03/01/2018
    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter